However, within the primary tumor, other than a slight increase in TH1 cells in mice treated with RCM (Supplemental Fig. S5), there was no additional activation of any immune pathways gained from adding the MerTK ASO to any other therapeutic modality (Fig. 4A, Supplemental Fig. S4A). Here, MERTK is linked to neoplasm.